Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Early data with the RIPTAC HLD-0915 look competitive.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
